Abstract: Slide Presentations |

Linezolid Is Well-Tolerated in Ventilator–Associated Pneumonia FREE TO VIEW

Greg J. Hooper, PhD; Rodney V. Croos-Dabrera, PhD; Sue K. Cammarata, MD
Author and Funding Information

Pharmacia, High Wycombe, UK


Chest. 2003;124(4_MeetingAbstracts):78S-c-79S. doi:10.1378/chest.124.4_MeetingAbstracts.78S-c
Text Size: A A A
Published online


PURPOSE:  Linezolid, the first approved oxazolidinone, has activity against gram-positive bacteria, including strains resistant to other antibiotics. We report the adverse event (AE) profile during linezolid use in nosocomial pneumonia for the subset of patients with ventilator-associated pneumonia (VAP).

METHODS:  AE data were pooled for the subset of patients with VAP from 2 identical, randomized, double blind, IV studies comparing linezolid (LZD) and vancomycin (VAN) in patients with gram positive nosocomial pneumonia. The investigator recorded and rated AEs as serious or non-serious, with judgment on severity by standard definitions, and assessed the relationship of AEs to study medication.

RESULTS:  544 VAP patients were treated (282 LZD, 262 VAN). There were no significant differences between groups in the number of patients with at least one AE (82% vs 84%, respectively), drug-related AEs (14% vs 12%), discontinuation due to drug-related AEs (1.4% vs 1.5%), serious AEs (37% vs 38%), or deaths (16% vs 20%). AEs ≥5%, regardless of causality, in LZD vs VAN groups, respectively, were diarrhea (13.1% vs 11.1%), fever (5.7% vs 6.1%), pneumonia (6.0% vs 7.3%), respiratory failure (8.2% vs 5.0%), sepsis (7.4% vs 9.5%), urinary tract infection (8.2% vs 7.3%), and vomiting (5.3% vs 5.3%). Additional AEs ≥5% were pressure sore (5.3%), nausea (5.0%) and hypertension (5.0%) in the LZD group, and rash (7.3%) and hypotension (5.0%) in the VAN group. The only AE in ≥2% of patients that was considered drug-related was diarrhea (4.3% LZD vs 2.3% VAN, p=.20). The most common serious AEs (≥3%) were related to patients’ underlying disease: respiratory and multi-organ failure for LZD and sepsis, pneumonia and respiratory failure for VAN.CONCLUSIONS: IV LZD is generally well tolerated in patients with ventilator-associated pneumonia. The nature and frequency of AEs were comparable in the LZD and VAN groups and were influenced by the severity of patients’ underlying disease.

CLINICAL IMPLICATIONS:  Linezolid is a reasonable therapeutic option, with no increased risk of adverse events, in the treatment of patients with VAP.

DISCLOSURE:  G.J. Hooper, Pharmacia employee, Industry.

Monday, October 27, 2003

8:00 AM - 9:30 AM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543